Fundamental Analysis of F-STAR THERAPEUTICS INC(NASDAQ:FSTX) stock

Fundamental Rating

Overall FSTX gets a fundamental rating of 2 out of 10. We evaluated FSTX against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of FSTX have multiple concerns. FSTX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

FSTX had negative earnings in the past year.

FSTX had a negative operating cash flow in the past year.

In the past 5 years FSTX always reported negative net income.

FSTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The profitability ratios for FSTX are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

FSTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FSTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

FSTX has more shares outstanding than it did 1 year ago.

Compared to 1 year ago, FSTX has a worse debt to assets ratio.

2.2 Solvency

FSTX has an Altman-Z score of 0.67. This is a bad value and indicates that FSTX is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.67, FSTX is in the better half of the industry, outperforming 61.16% of the companies in the same industry.

A Debt/Equity ratio of 0.15 indicates that FSTX is not too dependend on debt financing.

FSTX has a Debt to Equity ratio of 0.15. This is in the lower half of the industry: FSTX underperforms 65.72% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.15
Debt/FCF	N/A
Altman-Z	0.67

ROIC/WACCN/A

WACC8.16%

2.3 Liquidity

A Current Ratio of 3.38 indicates that FSTX has no problem at all paying its short term obligations.

FSTX's Current ratio of 3.38 is on the low side compared to the rest of the industry. FSTX is outperformed by 67.45% of its industry peers.

FSTX has a Quick Ratio of 3.38. This indicates that FSTX is financially healthy and has no problem in meeting its short term obligations.

FSTX's Quick ratio of 3.38 is on the low side compared to the rest of the industry. FSTX is outperformed by 66.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.38
Quick Ratio	3.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.57% over the past year.

The Revenue has grown by 18.64% in the past year. This is quite good.

Measured over the past years, FSTX shows a very strong growth in Revenue. The Revenue has been growing by 127.15% on average per year.

EPS 1Y (TTM)60.57%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-61.54%

Revenue 1Y (TTM)18.64%

Revenue growth 3YN/A

Revenue growth 5Y127.15%

Revenue growth Q2Q49.8%

3.2 Future

FSTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.63% yearly.

The Revenue is expected to grow by 12.21% on average over the next years. This is quite good.

EPS Next Y-39.55%

EPS Next 2Y-23.23%

EPS Next 3Y-11.79%

EPS Next 5Y5.63%

Revenue Next Year-70.62%

Revenue Next 2Y-69.75%

Revenue Next 3Y-37.51%

Revenue Next 5Y12.21%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

FSTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year FSTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

FSTX's earnings are expected to decrease with -11.79% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-23.23%

EPS Next 3Y-11.79%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for FSTX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

F-STAR THERAPEUTICS INC

NASDAQ:FSTX (3/8/2023, 7:00:00 PM)

After market: 7.12 0 (0%)

7.12

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap156.51M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.25

Health

		Industry Rank	Sector Rank
Debt/Equity	0.15
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.38
Quick Ratio	3.38
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)60.57%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-39.55%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)18.64%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

F-STAR THERAPEUTICS INC (FSTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens